Access to Innovative Treatments Act of 2026 has not moved since its introduction on Jun 24, 2026, with one cosponsor, a Republican
Written by the Congressional Research Service [2]. 116 words.
Access to Innovative Treatments Act of 2026 This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period. The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.
- Committees
- House Energy and Commerce Committee
House Ways and Means Committee - Policy area
- Health: 122 of 9,357 bills became law, 113th–118th (1.3%)
- Sponsor
- 2 of 110 bills enacted since 2013
- Text versions
- 1: introduced in house · 668 words
- Latest action
- Jun 24, 2026: Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Records
- Congress.gov · Bill text
The bill status record lists no related bills.